Nephrol Dial Transplant 2018 Mar 22. Epub 2018 Mar 22.
Department of respiratory medicine, Zhangjiajie City Hospital, Zhangjiajie, Hunan, China.
Download full-text PDF
Kidney Blood Press Res 2018 22;43(3):768-779. Epub 2018 May 22.
Background/aims: Whether angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB) could benefit patients with diabetes and albuminuria remains controversial. A systematic review and meta-analysis were conducted to answer this question by comparing ACE inhibitors or ARB with placebo among these patients.
Methods: In this meta-analysis, electronic data sources (Medline, the Cochrane Collaboration, and EMBASE) were searched. Read More
Medicine (Baltimore) 2015 Sep;94(39):e1560
From the Department of Cardiology, Shandong Provincial Qianfoshan Hospital, Shandong University (RX, SS, YH, LY, SH, GL, SY); and Shandong University of Traditional Chinese Medicine, Jinan, P.R. China (SS, YH, SH).
Although angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) belong to a family of therapies that block the renin-angiotensin system and are suggested to improve proteinuria/albuminuria, it is unclear which is more effective. To compare the effects of ACEIs and ARBs on proteinuria in primary hypertension by performing a meta-analysis covering randomized controlled trials (RCTs). We systematically searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from January 1990 to November 2014. Read More
PLoS Med 2016 Mar 8;13(3):e1001971. Epub 2016 Mar 8.
Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Background: Medications aimed at inhibiting the renin-angiotensin system (RAS) have been used extensively for preventing cardiovascular and renal complications in patients with diabetes, but data that compare their clinical effectiveness are limited. We aimed to compare the effects of classes of RAS blockers on cardiovascular and renal outcomes in adults with diabetes.
Methods And Findings: Eligible trials were identified by electronic searches in PubMed/MEDLINE and the Cochrane Database of Systematic Reviews (1 January 2004 to 17 July 2014). Read More
J Manag Care Pharm 2011 Oct;17(8 Suppl):S1-14
Duke Division of General Internal Medicine, Center for Health Services Research in Primary Care, Durham VA Medical Center, Durham, NC, USA.
Background: In 2007, the Agency for Healthcare Research and Quality (AHRQ) published a comparative effectiveness review (CER) on the benefits and risks of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) for treating essential hypertension in adults. The main findings indicated that the 2 classes of antihypertensive medications caused similar reductions in blood pressure, although higher rates of adverse events, especially cough, were reported by patients treated with ACEIs. In addition, the 2007 review indicated no treatment related differences in lipid levels, glycemic control, or progression of kidney disease among the agents. Read More